Effectiveness of Platelet-Rich Fibrin or Platelet-Rich Plasma in Mandibular Fracture Management: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis aimed to critically evaluate and synthesize the available evidence on the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in the management of mandibular and non-mandibular maxillofacial fractures. A comprehensive search of electronic databases was conducted up to February 2025 based on predefined inclusion criteria. The risk of bias in randomized controlled trials was assessed using the Cochrane Risk of Bias (ROB) tool, while the Newcastle-Ottawa Scale was applied to observational studies.

Prevalence of Oral Potentially Malignant Disorders in Smokeless Tobacco Users With or Without Areca Nut: A Meta-Analysis.

Background: Smokeless tobacco (SLT) use is a major global risk factor for oral potentially malignant disorders (OPMDs). However, the differential impact of SLT product composition, particularly tobacco-only versus combined tobacco-areca nut products, on OPMD prevalence remains inadequately characterized.

Objective: To compare the pooled prevalence of OPMDs between users of tobacco-only SLT and users of SLT containing both tobacco and areca nut.

Ductus Arteriosus Variability Linked to Maternal Drug Exposure: Assessment of the USFDA Adverse Event Reporting System using Disproportionality Analysis.

Introduction: The ductus arteriosus is a vital fetal vessel connecting the pulmonary artery to the aorta, facilitating blood flow away from the non-functional fetal lungs. Drug exposure during pregnancy may affect DA physiology, leading to conditions like premature DA closure, DA stenosis, or Patent Ductus Arteriosus (PDA). To identify drugs with maternal exposure that may be linked to alterations in the fetal and neonatal Ductus Arteriosus (DA).

Drug-Associated Alcohol Intolerance: A Real-World Disproportionality Analysis Study.

Alcohol intolerance, characterized by adverse reactions following alcohol consumption, can occur due to interactions between alcohol and certain medications. Despite its clinical significance, evidence for alcohol intolerance induced by commonly prescribed drugs remains limited. This study aimed to identify signals for drug-associated alcohol intolerance using the United States Food and Drug Administration (USFDA) Adverse Event Reporting System (AERS).

Assessing the power of AI: a comparative evaluation of large language models in generating patient education materials in dentistry.

Background: This study evaluates the use of large language models (LLMs) in generating Patient Education Materials (PEMs) for dental scenarios, focusing on their reliability, readability, understandability, and actionability. The study aimed to assess the performance of four LLMs-ChatGPT-4.0, Claude 3.

Sodium-Glucose Co-transporter-2 Inhibitors and Cardiac Function Parameters: A Network Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Background: Sodium-glucose Co-transporter-2 Inhibitors (SGLT2is) are recommended for heart failure based on clinical outcomes. However, there is a lack of evidence linking SGLT2is with changes in cardiac function parameters.

Aim: This study aimed to systematically evaluate the literature assessing the impact of SGLT2is on various cardiac parameters.

Enhanced Cytotoxicity and Receptor Modulation by SMA-WIN 55,212-2 Micelles in Glioblastoma Cells.

Glioblastoma (GBM), a devastating brain malignancy, resists conventional therapies due to molecular heterogeneity and the blood-brain barrier's significant restriction on drug delivery. Cannabinoids like WIN 55,212-2 show promise but are limited by poor solubility and systemic toxicity. To address these challenges, we evaluated styrene-maleic acid (SMA) micellar encapsulation of WIN 55,212-2 (SMA-WIN) against free WIN in epithelial (LN18) and mesenchymal (A172) GBM cell lines, targeting cytotoxicity and receptor modulation (CB1, CB2, TRPV1, PPAR-γ).

Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials.

Background: Polycystic ovary syndrome (PCOS) is a complex endocrine characterized by hyperandrogenism, hormonal imbalances, and metabolic disruptions, leading to reproductive complications and increased risk of cardiometabolic diseases. While lifestyle modifications are the cornerstone of PCOS management, pharmacological interventions, including metformin, oral contraceptives, and anti-androgens, are commonly utilized. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown promising results in PCOS management.

Drug-Associated Tendinopathies and Ligament Disorders: Results from a Retrospective Pharmacovigilance Study Using Disproportionality Analysis.

Tendinopathies and ligament disorders are significant musculoskeletal adverse events associated with various drugs, leading to restricted mobility and reduced quality of life. Although certain drug classes such as fluoroquinolones and corticosteroids have established links to these conditions, there is limited research on other potential drug associations. This study aimed to comprehensively evaluate drugs associated with tendinopathies and ligament disorders using data from the USFDA Adverse Event Reporting System (AERS).

Antiplatelet-Proton Pump Inhibitor Interactions and Arterial Thrombotic Events: A Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis.

Aims: The aim of this study is to evaluate the safety profiles of antiplatelet-proton pump inhibitors (PPIs) combinations and assess the clinical implications of their concurrent use in real-world settings through pharmacovigilance data analysis.

Background: The concomitant use of PPIs with antiplatelet therapy remains controversial due to potential drug interactions affecting clinical outcomes. While PPIs are recommended for gastroprotection in patients receiving antiplatelet therapy, concerns persist regarding their impact on antiplatelet efficacy, particularly with dual antiplatelet therapy (DAPT).

Nephrotoxicity risks of colistin-combination therapy: a USFDA adverse event reporting system analysis using disproportionality and interaction assessment.

Background: Colistin, a last-resort antimicrobial, is often used in combination with other drugs to treat multidrug-resistant infections, but its nephrotoxic potential raises concerns, especially in combination therapies.

Research Design And Methods: A retrospective analysis was performed on 29,163,222 reports from the USFDA Adverse Event Reporting System (AERS), identifying 125 reports meeting inclusion criteria for acute renal failure (ARF) associated with colistin-antimicrobial combinations. Disproportionality analysis using frequentists and Bayesian techniques were employed to evaluate ARF risk.

Genetic Determinants of Statin-induced Myopathy: A Network Metaanalysis of Observational Studies.

Introduction: Statin-induced myopathy (SIM) is a prevalent adverse event impacting treatment adherence. Despite extensive exploration of genotypes, conflicting evidence obscures their role in SIM incidence, prompting this network meta-analysis.

Methods: Observational studies meeting eligibility criteria (patients on any statin with reported SNPs and SIM details) were systematically reviewed.

Mapping the research landscape of oral appliances in obstructive sleep apnea: a bibliometric analysis of trends, influential publications, and emerging areas.

Background: Oral appliances (OAs) are widely used in the management of obstructive sleep apnea (OSA), yet a comprehensive understanding of the research landscape in this field is lacking. This study aims to map the global research trends, influential publications, leading researchers, and emerging areas of interest related to OAs for OSA.

Methodology: Data were retrieved from the Scopus.

Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study.

Background: Triple antithrombotic therapy (TAT), combining dual antiplatelet therapy (DAPT) with oral anticoagulants, is commonly used in patients requiring long-term anticoagulation following acute coronary syndrome or percutaneous coronary intervention. However, TAT may increase the risk of hemorrhage. There is a dearth of data regarding the risks of bleeding with various oral anticoagulants in TAT in comparison with DAPT and individual anticoagulants and antiplatelets due to which we carried out the present study examining the real-world pharmacovigilance data.

Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis.

Background: Drug-associated gingival disorders can negatively impact on oral health. This study aimed to utilize the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) to comprehensively assess the associations between medications and specific gingival disorders.

Methods: Data were extracted from the USFDA AERS from 2004-2024 using Preferred Terms for eight gingival disorders.

Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews.

Amlodipine has recently been incidentally reported with angioedema and is frequently prescribed with renin-angiotensin-aldosterone system inhibitors (RAAS-i) for hypertension management. While RAAS-i drugs are known to cause angioedema, the risk associated with amlodipine alone or in combination with RAAS-i drugs remains unclear. This study aimed to evaluate the association between amlodipine use and angioedema using pharmacovigilance data.

Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.

Background: Setmelanotide is approved for genetically determined obesity. While clinical trials and clinical evidence and practice provide some insights, a comprehensive assessment of its adverse event profile is needed that led to carrying out an assessment of reported adverse events in the USFDA Adverse Event Reporting System database, case reports and clinical trials.

Research Design And Methods: Multi-faceted analyses were carried out as follows: disproportionality measures employing frequentist and Bayesian methods; systematic review and meta-analysis (Medline, Cochrane CENTRAL and Google Scholar) generated-pooled estimates [proportion with 95% confidence intervals (CI)]; and published reports with adverse events to setmelanotide.

Ezetimibe-associated rhabdomyolysis: A comprehensive assessment of the USFDA adverse event reporting system using disproportionality analysis, case reviews, and meta-analysis of randomized clinical trials.

Background: Ezetimibe, a Niemann-Pick C1-like 1 inhibitor, is widely prescribed as a monotherapy or in combination with statins to reduce cholesterol levels. Although generally well-tolerated, concerns have emerged regarding the risk of rhabdomyolysis, particularly with combination therapies. This study aims to evaluate the association between ezetimibe and rhabdomyolysis using data from the United States Food and Drug Administration's Adverse Event Reporting System (USFDA AERS), case reviews, and a meta-analysis of clinical trials.

Monoclonal Antibodies and Small-Molecule Inhibitors Associated Osteonecrosis of Jaw: A Retrospective Pharmacovigilance Study.

Background: Osteonecrosis of the jaw (ONJ) is an adverse effect associated with medications such as monoclonal antibodies and small-molecule inhibitors.

Purpose: This study assesses the association between monoclonal antibodies and small-molecule inhibitors with ONJ.

Study Design, Setting, Sample: The study design was a retrospective pharmacovigilance case series.

Adverse drug event profile of pharmacotherapies for alcohol use disorder: a retrospective pharmacovigilance disproportionality analysis study.

Background: Alcohol Use Disorder (AUD) significantly affects global health, leading to physical deterioration and impacting personal and social relationships. This study aims to evaluate the adverse event profiles (AEP) of three USFDA-approved medications for AUD, acamprosate, disulfiram, and naltrexone, using data from the USFDA Adverse Event Reporting System (AERS).

Research Designs And Methods: Reports related to acamprosate, disulfiram, and naltrexone from March 2004 to March 2024 were extracted from the USFDA AERS database.

Hypouricemic effect of sodium glucose transporter-2 inhibitors: a network meta-analysis and meta-regression of randomized clinical trials.

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are known for their cardiovascular benefits, but their impact on serum uric acid levels is not well understood. This study evaluates the hypouricemic effects of SGLT2is and their potential cardiovascular implications.

Methods: A network meta-analysis was performed, including 56 studies (16,788 participants) contributing data to the meta-analysis.